The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

Sep-14

Endocrinology Healthcare Cost Pharmacoepidemiology

AUTHORS : Cheryl Neslusan, Janssen Scientific Affairs LLC, Titusville, NJ, USA – Email: cneslusa@its.jnj.com

JOURNAL : Diabetologia

REFERENCE: 57(S1):S330

DOI : 10.1007/s00125-014-3355-0

Read more

More publications

Jan-25

Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: a population-based cohort study

Pharmacoepidemiology

Read more

Jan-25

Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes

Pharmacoepidemiology

Read more

Nov-24

Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease

Pharmacoepidemiology

Read more